Dextra, in association with its parent Company, New Zealand Pharmaceuticals Ltd, will occupy booth number 1141 at Informex 2010 in San Francisco, on February 16 -19. Key marketing targets include custom manufacturing of API starting materials and APIs (with DMFs) with specialisation in carbohydrate and bile acid derivatives; pre-clinical and clinical materials with appropriate documentation; and analytical services. Dextra also offer a wide range of carbohydrates derivatives through its catalogue sales.  Dextra will release its updated and reformatted catalogue at Informex.